Abstract Submission opens on 17th February
Abstract Presentation Types
Oral Presentation
8 Minute presentation in the abstract sessions of the ESSO 44 scientific programme.
Poster in Spotlight
5 minute presentation during the coffee break at the poster in spotlight stations.
Poster will be also on display for the full congress.
ePoster Displayed
Poster on display on the ePoster screens for the whole duration of the congress.
Kindly note that this presentation type does not have a dedicated time slot.
Surgical Trial Proposal
Abstracts for proposals in the advanced stage of development, but not yet open for recruiting patients at the time of ESSO 44.
Top 3 highest scoring proposals will be presented during the Dragon’s Den session.
Abstract Guidelines
- Languages
- Authors and Co-Authors
- Abstract Title
- Abstract Structure
- Restrictions
- Abbreviations
- Abstract Platform
- Abstract Confirmation
- Abstract Review
- Deadline
The abstract must be submitted in good English. The Scientific Committee reserves the right to reject abstracts presented in poor English or request an immediate revision by the presenting author.
No more than 20 authors can be listed. E-mail address, institutional affiliation, city, and country must be filled in. For cooperative study groups, the group’s name should be used instead of individual institutional affiliations or include the group’s name in the abstract’s title.
The title of the abstract should be concise and accurately describe the study. Do not use non-standard abbreviations and commercial names (generic names only).
Abstracts should be structured to include the following 4 sections:
- Background: introductory sentence specifying the purpose of the study
- Material and methods: a brief description of relevant experimental procedures
- Results: summary of the results of the investigation
- Conclusion: a statement of the main conclusions
Only one data table is permitted in the body of the abstract. Illustrations and figures are not allowed and will be deleted if submitted.
Abbreviations may be used if standard or if spelled out and defined at the first use. Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e., “generic (Commercial ®)”.
Abstracts can only be submitted online.
Abstracts submitted by e-mail or fax will not be considered. The abstract submission system for the ESSO 44 will only be accessible on the congress website.
Step-by-step instructions will be provided within the submission system. Submitters can edit their abstracts until the deadline of 13 May 2025.
An e-mail confirming receipt of the abstract submitted online will be sent to the presenting author.
An abstract number will be allocated and should be mentioned for any queries relating to the submitted abstract.
Abstracts submitted for presentation at the ESSO 44 Congress will be reviewed by a panel of experts in the field of the subject and will be judged solely on the data submitted.
The final decision on the presentation format of all selected abstracts lies at the sole discretion of the Scientific Committee.
The submission deadline is 13 May 2025.
Abstract Topics
Abstract topics
How to Submit
Login to the ESSO Platform or create a new account.
Once logged in, click on the button ‘ESSO 44 Abstract submission’ to start your submission.
If you have not yet created an account, click on ‘Sign up’. Fill in all the required details, activate your account, and then you can start submitting your abstract.
Click on the button ‘New Abstract’ to start.
Check if your contact info is correct or adjust if needed.
The contact details should be of the submitter not the presenter (only if the submitter is not the same as the presenter).
You can indicate yourself or a co-author as a presenter later.
Select the main topic of your abstract. If your abstract covers two topics, you may select a second topic.
For Rare Tumours and Innovation and Technology abstracts we advice to choose the second topic to indicate the specific tumour site. This will help the review process.
If your topic is not listed, we can not accept the abstract.
Select your presentation preference.
Your preference will be taken into strong consideration, however, the Abstract Reviewers may adapt it based on the feedback.
This year we no longer accept ‘Surgical Trials in Progress’.
Write down the title of your abstract.
You will find guidelines about the title on the platform.
Your title is limited to 200 characters.
Once ready click on next.
Please indicate whether you have a conflict of interest or not.
If you have a conflict of interest to declare, fill it in the COI text box.
Please be as brief as possible.
Enter your abstract to the appropriate textbox.
Kindly note that the character limit is 2400.
For Surgical trial proposals please fill in the feasibility in the result box.
Write NA in the conclusions box.
Other guidelines can be found on the platform.
If you have co-authors, you can add them by clicking on the button ‘Add a new co-author’.
Fill in all the required details. You can add up to 20 co-authors.
Indicate in this step who the presenter will be. Confirmation of the submission will be sent to the presenter and submitter. the presenter will remain the further contact point.
Add keywords that are relevant to your abstract.
These keywords will be used to easily browse for posters on our congress platform.
You will have to add at least 1. You can add up to 9 keywords.
Please carefully check all the details you see in the confirmation tab.
If there is anything incorrect, please click ‘Back’ and correct it.
If everything is correct, you can proceed to submit or draft your abstract.
If you complete your submission, you can either click ‘Submit’ or ‘Save as Draft’.
If you submit, you will not be able to edit your abstract. If you select Save as Draft, you can return to make adjustments if needed.
Please note that abstracts in draft are not automatically submitted upon the deadline.
If you submitted or drafted an abstract, you will receive a confirmation email.
Kindly note that a drafted abstract does not mean abstract submission.
The review starts immediately after the abstract submission deadline.
The results will be available in the first week of July. The indicated presenters will be informed.
Abstract Policies and Regulations
With the submission of an abstract to ESSO 44 Congress, the presenting author:
- Accepts responsibility for the accuracy of the submitted abstract.
- Accepts to be the contact person for all correspondence regarding the abstract and informs co-authors of its status.
- Confirms that all authors are aware of and agree to the content of the abstract and support the data presented.
- Warrants that the data and conclusions presented in the abstract have not been published in the same format and with the same title prior to the date of the ESSO 44 congress.
- States that for all studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and informed consent given where appropriate.
- Identifies, obtains and discloses any financial interest in products or processes described in the abstract for all abstract authors. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research, and other substantive relationships.
- Releases the copyright on behalf of all authors to ESSO and gives permission for the abstract, when selected for presentation, to be published in an issue of EJSO- the European Journal of Surgical Oncology, as well as on the ESSO 44 website. The copyright of the abstract remains with the author(s).
- Commits to register and attend ESSO 44 if the abstract is selected*. Costs associated with the submission and presentation of an abstract are the responsibility of the presenter. Selected abstracts will only be published in EJSO if the presenting author is registered and attends the Congress in person.
* In case the presenting author is not able or available to present the accepted abstract, a co-author must be appointed to present the abstract and must be registered, please inform the ESSO Secretariat at congress@essoweb.org about this change.